SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion.
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: StocksDATsoar who wrote (54805)7/17/2000 12:45:09 AM
From: Jim Bishop   of 150070
 
CLYC here's an interesting post on RB:

ragingbull.altavista.com

By: genomic1 $
Reply To: 314 by MamboMerchant $$$
Sunday, 16 Jul 2000 at 11:46 PM EDT
Post # of 325

MM--I disagree with your statement that this technology is easily duplicated. First of all, I am assuming that when you say
"technology" that you are referring to DNAPrint Genomic's "platform". As you may know, up to now all efforts in this area
have gone mostly to help create a reference DNA (the human genome project) which has taken billions of dollars and is
the equivalent of putting a man on the moon. Now that it is nearing completion, the next big application will be the
interpretation of how genetic diversity affects the efficacy and side effects of drugs (a field called "personalized
medicine"). Most studies so far that have been looking into the genetic basis for disease have focused on a defect in a
single gene (ie. breast cancer-BRCA1 gene or sickle-cell anemia). However, most diseases are not single gene defects
but are the result of complex interactions between several genes (these multi-gene defects are where DNAPrint
Genomics is concentrating).

Now, why are most all companies avoiding concentrating on diseases caused by multigenetic interactions????

Here is why..... in order to identify these different genes one must have access to sophisticated algorithms and software
with fuzzy logic neural net design that can recognize the patterns among hundreds of thousands of genes that make one
susceptible to a disease or make one a positive/negative receptor to a drug. This takes more than just a bunch of
scientists in a lab, but a "dream team" with a skill set that combines knowledge of software programming, statistics, novel
math modeling techniques, and molecular genetics. Currently, no other company that I know of exists that has these
attributes.

Now, will other companies eventually hire the people that have these skills? Well, I would guess that they would, but if you
check with human resources at the big genomic companies now you will find few soliciting for high-level mathematicians.

Note: first mover advantage is extremely valuable in this field. Why? Because you can patent these "solutions" if they have
utility.

One final question: What is a patent worth on the gene that determines cancer?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News